



CK2 (alpha/beta) Positive Control

Product Data Sheet

For Research Use Only, Not for use in diagnostic procedures

CK2 (alpha/beta) Positive Control

(Human, full length, recombinant enzyme expressed in *E. coli*.)

Cat# CY-E1170-1

Lot No.

For 200 assays

(0.04 units / μL x 100 μL)

Product Description: Human full length CK2-alpha and -beta, containing a C-terminal His-tag, expressed in *E. coli*. Purified by Ni-NTA agarose chromatography. The CK2 (alpha/beta) Positive control is designed to use for CycLex CK2 Kinase Assay/Inhibitor Screening Kit [Cat# CY-1170]. The CK2 (alpha/beta) Positive Control should be added to the well at 20 m units/well. For instance, dilute the Positive Control 1:20, use 10 μL for 1 assay. Unused CK2 (alpha/beta) Positive Control should be stored at below -70°C .

Product Size: Full length CK2-alpha and CK2-beta: 4 units/100 μL

Formulation: The CK2 (alpha/beta) Positive Control is supplied frozen in a buffer containing 20mM HEPES-KOH (pH 7.5), 1 % BSA, 1 mM DTT, 50mM NaCl, 0.03 % Brij35 and 50 % glycerol.

Source: Human full length CK2 (alpha/beta), containing C-terminal His-tag, expressed in *E. coli*.

Molecular Weight: CK2 (alpha/beta) demonstrates a 43 kDa and 30 kDa bands respectively by SDS-PAGE analysis.

Purity: CK2 (alpha/beta) is greater than 65 % pure as determined by SDS-PAGE analysis.

Substrates: CK2 (alpha/beta) phosphorylates a numerous of substrates, including DNA topoisomerase I, human Cdc34 and p53

Inhibitors: Heparin and tetrabromobenzotriazole (TBB) are known as effective CK2 inhibitor.

Unit Definitions: One unit is defined as the amount of kinase required to incorporate 1 nmol of phosphate into the GST-p53, per minute at 30°C .

Assay Conditions: Assay activity of CK2 (alpha/beta) in a 50 μL reaction containing 20 mM Hepes KOH (pH 7.5), 5 mM MgCl_2 , 1 mM DTT, 50 μM [γ ^{32}P] ATP (1 μCi), and 4 μg of GST-p53 fusion protein. Start the reaction by adding 10 μL of the enzyme, diluted 50-fold in a buffer containing 20 mM Hepes KOH (pH 7.5), 1 mM DTT, 0.03 % Brij35. Incubate for 30 minutes at 30°C . Terminate the reaction by adding 600 μL of cold 10 % TCA solution containing 0.2 % sodium pyrophosphate and stand on ice for 15 min. Filtrate acid insoluble material through GFC filters (Whatman Inc.), wash 4 times with 1 % TCA and rinse filters with ethanol. Dry filters and count in a liquid scintillation counter.

Storage and Stability: Stable for 12 months at -70°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot enzyme to avoid repeated freezing and thawing.

Related Products:

* CK2 (alpha/beta) Positive Control: Cat# CY-E1170-2

* CK2 assay/Inhibitor Screening Kit: Cat# CY-1170



CK2 (alpha/beta) Positive Control

Product Data Sheet

For Research Use Only, Not for use in diagnostic procedures

* Anti-phospho-p53 S46 (TK-4D4) monoclonal antibody: Cat# CY-M1022 :Available soon

General References:

1. Lozeman, F.J., Litchfield, D.W., Piening, C., Takio, K., Walsh, K.A. and Krebs, E.G. (1990) Isolation and characterization of human cDNA clones encoding the α and α' subunits of CK2. *Biochemistry* 29, 8436–8447
2. Litchfield, D.W., Lozeman, F.J., Piening, C., Sommercorn, J., Takio, K., Walsh, K.A. and Krebs, E.G. (1990) Subunit structure of CK2 from bovine testis: demonstration that the α and α' subunits are distinct polypeptides. *J. Biol. Chem.* 265, 7638–7644
3. Maridor, G., Park, W., Krek, W. and Nigg, E.A. (1991) CK2. cDNA sequences, developmental expression and tissue distribution of mRNAs for α , α' and β subunits of the chicken enzyme. *J. Biol. Chem.* 266, 2362–2368
4. Munstermann, U., Fritz, G., Seitz, G., Lu, Y.P., Schneider, H.R. and Issinger, O.-G. (1990) CK2 is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. *Eur. J. Biochem.* 189, 251–257
5. Pepperkok, R., Lorenz, P., Ansorge, W. and Pyerin, W. (1994) CK2 is required for transition of G0/G1, early G1, and G1/S phases of the cell cycle. *J. Biol. Chem.* 269, 6986–6991
6. Landesman-Bollag, E., Romieu-Mourez, R., Song, D.H., Sonenshein, G.E., Cardiff, R.D. and Seldin, D.C. (2001) Protein kinase CK2 in mammary gland tumorigenesis. *Oncogene* 20, 3247–3257
7. Seldin, D.C. and Leder, P. (1995) CK2 α transgene-induce murine lymphoma: relation to theileriosis in cattle. *Science* 267, 894–897
8. Landesman-Bollag, E., Channavajhala, P.L., Cardiff, R.D. and Seldin, D.C. (1998) p53 deficiency and misexpression of protein kinase CK2a collaborate in the development of thymic lymphomas in mice. *Oncogene* 16, 2965–2974
9. Channavajhala, P. and Seldin, D.C. (2002) Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. *Oncogene* 21, 5280–5288
10. Sayed, M., Pelech, S., Wong, C., Marotta, A. and Salh, B. (2001) Protein kinase CK2 is involved in G2 arrest and apoptosis following spindle damage in epithelial cells. *Oncogene* 20, 6994–7005
11. Desagher, S., Osen-Sand, A., Montessuit, S., Magnenat, E., Vilbois, F., Hochmann, A., Journot, L., Antonsson, B. and Martinou, J.C. (2001) Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. *Mol. Cell* 8, 601–611
12. Li, P., Li, J., Muller, E., Otto, A., Dietz, R. and von Harsdorf, R. (2002) Phosphorylation by protein kinase CK2. A signaling switch for the caspase-inhibiting protein ARC. *Mol. Cell* 10, 247–258
13. Wang, H., Davis, A., Yu, S. and Ahmed, K. (2001) Response of cancer cells to molecular interruption of the CK2 signal. *Mol. Cell. Biochem.* 227, 167–174

PRODUCED BY

CycLex Co., Ltd.
1063-103 Terasawaoka
Ina, Nagano 396-0002
Japan
Fax: +81-265-76-7618
e-mail: info@cyclex.co.jp
URL: <http://www.cyclex.co.jp>

CycLex/CircuLex products are supplied for research use only. CycLex/CircuLex products and components thereof may not be resold, modified for resale, or used to manufacture commercial products without prior written approval from CycLex Co., Ltd.. To inquire about licensing for such commercial use, please contact us via email.